Genetic changes in HER2, PTEN, PIK3CA and AKT1 are all common in breast cancer and lead to the elevated phosphorylation of downstream targets of the PI3K/AKT signalling pathway. Changes in HER2, PTEN, PIK3CA and AKT have all been reported to lead to both enhanced proliferation and failures in hollow lumen formation in three dimensional epithelial culture models, but it is not clear whether these failures in lumen formation are caused by any failure in the spatial coordination of lumen formation (hollowing) or purely a failure in the apoptosis and clearance of luminal cells (cavitation). Here, we use normal murine mammary gland (NMuMG) epithelial cells, which form a hollow lumen without significant apoptosis, to compare the transformation by these four genetic changes. We find that either mutant PIK3CA expression or PTEN loss, but not mutant AKT1 E17K, cause disrupted epithelial architecture, whereas HER2 overexpression drives strong proliferation without affecting lumen formation in these cells. We also show that PTEN requires both lipid and protein phosphatase activity, its extreme C-terminal PDZ binding sequence and probably Myosin 5A to control lumen formation through a mechanism that does not correlate with its ability to control AKT, but which is selectively lost through mutation in some tumours. These findings correlate AKT-independent signalling activated by mutant PIK3CA or PTEN loss, but not strongly by HER2, with disrupted epithelial architecture and tumour formation.
INTRODUCTION
Class I phosphoinositide 3-kinase (PI3K) is a lipid kinase activated by many cell surface receptors, including receptor tyrosine kinases such as HER2. Its lipid product, PtdInsP 3 , promotes the activation of downstream signalling molecules, such as AKT, mTOR and RAC, and this activation is inhibited by the tumour suppressor, PTEN, which metabolises PtdInsP 3 .
1,2 Genetic changes that activate signalling through receptor tyrosine kinases and the downstream PI3K pathway occur in many and perhaps most cancers, with the frequency of activation of PI3K signalling being particularly high in cancers derived from epithelial tissues (carcinomas). 1, 3 In B20% of breast carcinoma, amplification of the HER2 gene (also known as ErbB2 or neu) leads to overexpression of the protein. Around a third of breast cancers display a mutation or deletion of at least one copy of the PTEN gene, 25% have an activating mutation in PIK3CA, which encodes the p110a component of PI3K and around 5% have an activating mutation in AKT1. [4] [5] [6] [7] [8] The causal role of these PI3K pathway mutations in breast cancer has been supported by the rapid development of mammary tumours in mice either lacking Pten or expressing an active mutant PIK3CA H1047R selectively in the breast. [9] [10] [11] Additionally, the identification of PIK3CA mutations in early-stage tumours suggests that their selection may be an early event in mammary tumorigenesis 12 but the co-existence of multiple genetic changes in different PI3K pathway components implies that these changes may be selected independently. 3 Altered PI3K pathway activity appears to contribute to the regulation of many different cellular processes but is most consistently associated with the control of cell proliferation, growth, survival, metabolic reprogramming, motility and polarity. 2, [13] [14] [15] These effects are mediated through a large and diverse group of proteins that can bind selectively to the PtdInsP 3 lipid, the best studied of which are the AKT kinases. 2 It appears that the deregulation of cell growth and survival downstream of mutated PI3K/PTEN is important in mammary tumour development, mediated in large part through the Akt kinases, particularly Akt1. [16] [17] [18] [19] However, it also appears that the loss of cell polarity and tissue architecture can itself be an important driver of some breast tumours, rather than just a by-product of unchecked proliferation. [20] [21] [22] [23] Attempts to study the detailed effects of PI3K pathway driven transformation on both cell proliferation and tissue morphology have used 3D models of epithelial cell culture that more closely recapitulate breast pathophysiology than simple adherent culture. In these models, several types of primary and immortal mammary epithelial cells give rise to spherical colonies with a single hollow lumen. However, in separate studies, cells lacking PTEN, 24 expressing oncogenic mutants of p110a 25 or AKT1, 26 or overexpressing HER2, 27 have each been found to display aberrant tissue architecture and fail to form a single hollow lumen. On the other hand, expression of mutant AKT1 E17K from the endogenous gene in engineered MCF10A cells did not cause morphological changes, in contrast to mutant PIK3CA expression. 28 Because lumen formation in different cell models appears to proceed both via spatial cell separation at a nascent apical surface and via apoptosis of residual luminal cells, 29 the mechanisms by which PI3K pathway transformation affects lumen formation is unclear. As there is an expectation that druggable steps downstream of PI3K, particularly AKT and perhaps mTOR may be responsible for the aberrant luminal cell survival, but other poorly characterised pathways may be responsible for the spatial co-ordination of cell separation, 24, 30, 31 these issues could influence cancer treatment.
In this study, we have used an untransformed mammary epithelial cell line NMuMG, to compare transformation by loss of PTEN expression, expression of mutant p110a or mutant AKT1 E17K or by overexpression of HER2. We have also investigated in more detail the mechanisms by which PTEN controls epithelial morphogenesis. We find that oncogenic PIK3CA activity or loss of PTEN in NMuMG cells lead to dysregulated epithelial polarisation and morphogenesis via mechanisms that appear independent of AKT. In contrast, HER2 overexpression provides a strong proliferative signal, but does not disrupt polarisation and tissue architecture.
RESULTS
To study in detail the effects of PTEN loss on epithelial tissue architecture and to study its mechanisms of action in these settings, we used RNA interference to reduce PTEN expression in two untransformed epithelial cell lines, Madin-Darby canine kidney (MDCK) cells and normal murine mammary gland cells. Stable cell clones of MDCK expressing PTEN-targeting shRNA were selected, and in both MDCK and NMuMG cells, polyclonal genome-integrating lentiviral shRNAs were used to knock down PTEN expression. When seeded as single cells into 3D matrigel suspension culture, both MDCK and NMuMG cells formed colonies with a single hollow lumen and appropriate localisation of analysed adherens and tight junction proteins including beta catenin and occludin ( Figure 1 and Supplementary Figure S1 ). The effect of reduced PTEN expression on 3D colony morphology was analysed in cells transduced with shRNA-encoding lentiviruses and then seeded into 3D matrigel suspension culture. In both MDCK and NMuMG lines, cells lacking PTEN displayed a failure to form a single hollow lumen, mislocalisation of junctional markers and also elevated phosphorylation of the downstream kinase AKT (Figures 1a, b, d and e and Supplementary Figure S1 ). This aberrant 3D culture phenotype could be rescued by lentiviral re-expression of wild-type RNAi-resistant PTEN (Figure 1c and see below), giving confidence that it was caused by reduced PTEN expression. We analysed apoptosis by staining for cleaved caspase 3 in these cultures, and in agreement with existing data, 29, [32] [33] [34] our MDCK cultures showed significant apoptosis of luminal cells occurring during hollow cyst formation, which we found to occur slowly between 5 and 10 days. In contrast, little or no apoptosis was observed with MDCK cells lacking PTEN (Figure 1f ). In the NMuMG cultures, lumen formation appeared to occur at around the 3-day stage and significant luminal apoptosis was not observed in cells analysed between 3 and 9 days (Figure 1g and Supplementary Figure S1 and data not shown). Immunofluorescent analysis of 3D polarised NMuMG cell colonies implied a modest enrichment of PTEN near the apical surface of these cells (Supplementary Figure S2 ) that is similar but weaker than the localisation of the the apical membrane marker atypical PKC (Supplementary Figure  S1 ) and consistent with previous data from MDCK and T84 cells 24 and from the chick epiblast. 35 We tested the ability of PI3K inhibitors to rescue the phenotype caused by PTEN knockdown in both MDCK and NMuMG cells. Doses of inhibitor were identified that would reverse the increased AKT phosphorylation induced by PTEN knockdown in adherent culture and tested for their effects on 3D morphology. LY294002 (10 mM ) was able to achieve an almost full rescue of hollow lumen formation in MDCK PTEN knockdown cells (Supplementary Figure  S3a and b) . Similarly in NMuMG cells with reduced PTEN, optimal concentrations of LY294002 (5 mM) and GDC0941 (100 nM) were also able to rescue the phenotype of many cell colonies (Figures 2a-c and Supplementary Figure S4 ). Higher doses of PI3K inhibitors often inhibited colony formation entirely, particularly in NMuMG cells.
Many mammary carcinoma cell lines are able to proliferate in 3D culture, although to our knowledge none have been reported to consistently form hollow acini. Therefore, we tested whether PI3K inhibitors might allow mammary carcinoma cell lines to undergo luminal hollowing, including some lines carrying mutations of PTEN or PI3K. Six breast cancer cell lines were found to proliferate suspended in 3D matrigel culture: MDA-MB-468 and MDA-MB-453, both of which carry a PTEN mutation/deletion, MCF-7, T47D and BT-20, which all carry an activating PIK3CA mutation (see below), and MDA-MB-231 cells. Of these cell lines, only BT20 were able to form hollow acini at any significant level (B25% of colonies), but this hollow lumen formation was not increased by PI3K inhibition (Supplementary Figure S5) . Similarly, attempts to drive hollow lumen formation in MDA-MB-468 cells by the expression of wild-type PTEN were unsuccessful, despite successful suppression of AKT phosphorylation (data not shown and Figures 5 and 6 ).
Previous work in adherent MDCK cells reported that PTEN knockdown caused a failure in tight junction formation as detected by peripheral ZO-1 localisation during recovery from calcium depletion. 36 We have found a similar failure in adherent cell junction formation in PTEN knockdown NMuMG cells, detected by peripheral localisation of the tight junction components ZO-1 and occludin, and also filamentous actin (F-actin) during recovery from either trypsinisation (Figure 3a ) or calcium depletion (Supplementary Figure S6) . We also observed a similar, significant, but weaker effect on adherens junction formation (Supplementary Figure S7) . In addition, if lentiviruses were used to knock down PTEN expression in already established NMuMG cultures, no disturbance of adherent cell peripheral ZO-1 localisation or 3D cultured cell lumen morphology was observed ( Figure 3b and Supplementary Figure S8 ). Finally, if the PI3K inhibitor LY294002 was added to aberrant multi-luminal MDCK colonies after 10 days in culture, a single hollow lumen did not arise over the next 10 days of culture (Supplementary Figure S9 ). Several detailed mechanisms by which PTEN and PI3K control cell survival acting via AKT have been previously described. 17 Therefore, in order to investigate the poorly understood mechanisms by which PI3K signalling affects the spatial regulation of epithelial architecture, we chose to perform most of our experiments using NMuMG cells, in which hollow lumen formation appeared to be independent of apoptosis.
Mammary epithelial cell transformation by p110a, AKT1, HER2 and PTEN To directly compare the details of cell transformation by different genetic changes that activate PI3K signalling in breast cancers, we engineered NMuMG cells to express oncogenic mutant p110a or AKT1 at similar levels to the endogenous proteins, to overexpress wild-type HER2 to levels seen in human breast cancers or to express greatly reduced levels of PTEN as described above. Both engineered expression and knockdown were achieved using genome-integrating lentiviruses, and because viruses encoding the larger proteins, HER2 and p110a, displayed lower transduction efficiencies (B5-20% of cell population), in all cases, transduced polyclonal target cell populations were selected with antibiotics over a period of several days. Each of these changes caused a modest upregulation in AKT phosphorylation (Figure 4) . Transduced cell populations were then analysed for junction formation in adherent culture and lumen formation in 3D matrigel culture. Expression of either p110a H1047R or p110a E545K caused a significant reduction in the ability of NMuMG cell colonies to form a single hollow lumen in 3D culture, which was not observed with engineered expression of wild-type p110a or in vector controls. However, these mutant PI3K isoforms did not lead to a significant disruption in adherent cell junction formation as visualised by peripheral ZO-1 staining (Figure 4d) . In MCF10A cells, overexpression of either HER2 or activated AKT leads to aberrant proliferation, luminal cell survival and disruption of acinar architecture. 26, 27 In contrast, we found that in NMuMG cells, neither expression of AKT1 E17K nor overexpression of HER2 had a significant effect either on 3D lumen formation or adherent cell junction formation (Figures 4g-k) . It should be noted that in 3D culture, HER2 overexpression led to an increase in proliferation ( Figure 4m) [37] [38] [39] In order to test the function of different PTEN mutants in NMuMG cells, we made silent mutations in the PTEN cDNA making it resistant to our PTEN-targeting shRNA-mediated knockdown. This allowed us to perform polyclonal gene replacement experiments at physiological expression levels. PTEN knockdown led to the expected failure in hollow lumen formation and this was not rescued by expression of green fluorescent protein, but could be rescued by re-expression of human wild-type PTEN. Catalytically inactive PTEN (C124S) was unable to rescue lumen formation, but interestingly, neither lipid nor protein phosphatase activities appeared sufficient to rescue lumen formation, even when PTEN Y138L and PTEN G129E were co-expressed together in the same cells ( Figure 5) .
To further study the separable effects of PI3K signalling on lumen formation via spatial hollowing and via apoptosis-associated cavitation, we compared the effects of inhibitors of PI3K and AKT and of expressed mutants of PTEN, in NMuMG and MDCK cells. In NMuMG cells, PI3K inhibition was able to rescue the disrupted lumen formation caused by PTEN knockdown, but this was not rescued by an AKT inhibitor or expression of PTEN Y138L. In contrast , lumen formation in PTEN knockdown MDCK cells was rescued by inhibitors of either PI3K or AKT and was also achieved by the PTEN mutant Y138L (Supplementary Figure S4) . These data correlate hollow lumen formation in MDCK cells, but not NMuMG, with observable luminal apoptosis that can be suppressed by survival signalling mediated by the AKT branch of the PI3K pathway.
We recently showed the apparent requirement for both lipid and protein phosphatase activity within the same PTEN molecule in studies of glioma cell invasion. 39 In these glioma studies, PTEN appeared to autodephosphorylate a site in its C-terminal tail, Thr366, promoting lipid phosphatase-dependent regulation of invasion. 39 To investigate further whether a similar role for PTEN's protein phosphatase activity and Thr366 phosphorylation might be acting in the regulation of epithelial morphology, we investigated whether mutation of Thr366 would overcome the apparent requirement for protein phosphatase activity in the ability of PTEN to support epithelial morphogenesis. Significantly, a double mutant, combining PTEN Y138L with an unphosphorylatable Thr366Ala mutation, was able to support normal NMuMG cell lumen formation, unlike PTEN Y138L, removing the apparent requirement for protein phosphatase activity (Figures 6a and b) . It has been proposed that PTEN's PtdInsP 3 phosphatase activity, targeted through interaction with PDZ-domain containing scaffolds, including Par3, is critical for its role in regulating epithelial morphogenesis. 31, 36, 40 Consistent with this proposal, a PTEN mutant unable to engage in PDZ-mediated protein-protein interactions, PTEN Q399X, is also unable to rescue morphogenesis in PTEN knockdown NMuMG cells (Figures 6a and  b ). Finally, we tested two tumour-derived PTEN mutants. PTEN Y138C, identified in a small cell lung carcinoma that selectively lacks protein phosphatase activity and PTEN X404L in which a leucine replaces the stop codon, causing an eight amino acid extension and blocking the interaction with PDZ domain containing binding partners. Both of these mutants retain lipid phosphatase activity and the ability to control cellular AKT, but also fail to support NMuMG lumen formation in place of wild-type PTEN. This last result suggests that in the tumours in which these mutants originated, the selection for these PTEN mutations was driven by the dysregulation of PTEN-regulated signalling mechanisms other than AKT and that correlate with its control of epithelial morphogenesis.
The failure of the mutant PTEN proteins Q399X and X404L to support hollow lumen formation correlates with their inability to bind to several PDZ-domain containing binding partners and suggests a requirement for PTEN to associate with protein complexes, probably including those of which Par3 is a component. 31, 36 Therefore, to further investigate such mechanisms of PTEN regulation, we investigated the effects on (Figure 6d ). To follow up this possibility further for Myosin Va, we used a lentiviral approach to overexpress a dominant negative cargo binding globular domain of MyoVa (MyoVa-G), 42 which was also found to disrupt hollow lumen formation (Figure 6e ). AKT phosphorylation was unaffected by MyoVa-G until the highest levels of expression were achieved, suggesting that modest overexpression of MyoVa-G expression did not simply sequester all cellular PTEN in an inactive state (Figure 6d and data not shown).
DISCUSSION
Genetic changes in HER2, PTEN, PIK3CA and AKT1 are all common in breast cancer. All these changes generally result in the activation of AKT and phosphorylation of its downstream substrates, and this AKT-dependent response appears to be an important driver of tumorigenesis, including the suppression of tumour cell apoptosis. 17 However, changes in PIK3CA and PTEN affect many AKT-independent pathways, several related to cell motility and polarity, and HER2 additionally activates PI3K-independent signalling molecules, such as PLCg and RAF. Questions remain therefore whether these studied genetic changes drive tumour development principally through a shared AKT-dependent mechanism, or whether AKT is only one of several key responses that mediate the effects of HER2 or PI3K activation or PTEN loss. We have modelled these genetic changes in cultured mammary epithelial cells using expression levels of wild-type or mutant proteins within ranges that occur in human cancers. In experiments using NMuMG cells that appear to distinguish the recognised AKT-related effects on luminal cell apoptosis from spatial coordination mechanisms that produce a lumen by hollowing, we found that only oncogenic PI3K mutants and PTEN loss disrupted these latter polarised, spatially co-ordinated processes. Although this does not detract from the pathological significance of AKT driven survival signalling, evidence supports the importance of these polarity-related mechanisms in carcinoma development. First in this study, we show that the lung carcinomaderived PTEN mutant, PTEN Y138C, and also PTEN X404L, one of three mutants identified in glioblastoma with disruption of the PTEN stop codon, are selectively impaired in their ability to control lumen formation, but not AKT. Second, in breast and other tumour types, there is a far lower frequency of mutations detected in AKT than upstream changes in PTEN or PIK3CA. 1 Also, more generally, loss of polarity regulators such as scribble promotes both disruption of epithelial architecture and tumour formation. 22, 23 Therefore, we feel our data provide further support for the significance of polarity regulation in tumour development driven by PTEN loss and PIK3CA mutation, but not HER2 amplification. Here, it seems significant that either loss of PTEN or oncogenic activation of p110a not only increase PtdInsP 3 levels but also remove spatiotemporal control over localisation-dependent functions for this lipid signal. 2, 15, 24, 31 The effects of dysregulated PI3K-dependent signalling in epithelia in vivo have been most widely studied using (B10) mice in which Pten has been genetically deleted from specific epithelial tissues or organs. 43 The phenotype of these epithelia is extremely diverse. For example, deletion of Pten from the adult small intestine has little or no short-term morphological or proliferative effect, 44 whereas deletion of Pten from the retinal pigment epithelium led to a widespread failure in cell-cell adhesion, an epithelial to mesenchymal transition and loss of this tissue. 45 In most cases, however, disruption of epithelial morphology is limited but in almost all cases tumours arise as the mice grow older 43 indicating that this tumour formation relies upon a combination of Pten loss with other low-frequency events. These findings are consistent with the hypothesis that PTEN is not required for the maintenance of tissue integrity in most epithelia, but that it can have an important role in certain settings of de novo polarisation, junction formation and tissue morphogenesis when other supportive polarity cues are absent.
It is significant that whereas most mutations of PTEN identified in tumours are functional null alleles that provide little insight into the mechanisms by which PTEN activity affects tumour development, some tumour-associated PTEN mutants are functionally selective and retain activity in some functional assays. 46 We show that two tumour-derived mutants, that retain the ability to control AKT, fail to support NMuMG cell lumen formation. This implies that in these tumours, the selective pressure driving PTEN mutation was from the deregulation of PTEN regulated signalling mechanisms that do not include AKT and that correlate with lumen formation. The apparent requirement for the C-terminal binding sequence of PTEN for lumen formation would seem to implicate PDZ domain-dependent protein-protein interactions in such a mechanism.
Our data using NMuMG cells show that in some cases, HER2 transformed mammary epithelial cells, despite being hyperproliferative, are capable of establishing and maintaining normal 3D tissue architecture. This contrasts somewhat with recent work 47 showing luminal translocation of single HER2/ERBB2 expressing MCF10A cells in pre-formed normal hollow acini. This would seem to imply that a key determinant of this luminal translocation is the recognition of differences between the transformed HER2 expressing cell and surrounding cells, consistent with existing models. 48 In our work, PTEN loss from established hollow NMuMG acini does not affect their morphology. However, it is the establishment of normal 3D epithelial morphology that is disrupted by PTEN loss or by mutant p110a and the selective phenotypic disruption we observe with certain tumour-derived PTEN mutants correlates this signalling capability with tumour formation.
The expression of mutant p110a had similar effects to PTEN knockdown on 3D tissue morphology but unlike PTEN knockdown, did not lead to an obvious disruption in junction formation in adherent culture (Figure 4) . It is unclear whether this reflects an unrecognised difference between the signalling mechanisms activated by these two events, or is due to experimental differences. The 2D junction formation assay seems less sensitive to PTEN knockdown (that is, requires very efficient knockdown before a strong phenotype is observed). Also, the observed effect of mutant p110a on 3D morphology is weaker than that of PTEN KD (Figure 4 and data not shown). Therefore, it seems possible that the observed lack of effect of mutant p110a on 2D junction formation may be due to a quantitatively weaker effect than PTEN KD to disrupt one signalling mechanism that affects both 2D and 3D phenotype, rather than qualitatively different effects to disrupt signalling.
It is unclear how PTEN and PI3K control epithelial lumen formation independently of AKT. Data using shRNA targeting known PTEN binding proteins 36, 41, 42 provides support for a role for Par3, Nherf1 and MyoVa in this process (Figure 6d ). This was supported for MyoVa by the similar disrupted phenotype caused by a dominant negative MyoVa construct (Figure 6e ). These data implicate the precise localisation of PTEN activity in the regulation of lumen formation, but detailed understanding of the regulatory mechanisms involved will require extensive further study.
Our data support previous findings that downstream of class I PI3K and PTEN, separable pathways preferentially control cell proliferation or tissue morphology. 2, 17, 30, 49 We now show that HER2 overexpression can activate PI3K/AKT yet selectively drive proliferation in the absence of effects on tissue morphology. On the other hand, the identification of pathology associated PTEN mutations that selectively disrupt the ability of the phosphatase to control epithelial tissue morphology implicate the importance in tumour formation of signalling mechanisms downstream of PTEN and PI3K that control morphology. These multiple distinct PI3K-dependent effects on tumour formation provide further insight explaining the apparently frequent independent occurrence of genetic changes in HER2, PIK3CA and PTEN in breast cancer and other tumour types 3 and should provide the detailed understanding of this signalling network required for the successful development and application of targeted therapies.
MATERIALS AND METHODS

Cell culture and cell based assays
NMuMG were obtained from ECACC/HPA (Porton Down, UK) and grown in DMEM (Dulbecco's modified Eagle's medium):F12 (1:1) (Invitrogen, Paisley, UK) with supplements: estradiol (100 pM), hydrocortisone (1 mM), epidermal growth factor (Calbiochem, Merck Chemicals UK, Nottingham, UK, 10 ng/ml), insulin (250 ng/ml), prolactin (Sigma, Poole, UK, 0.25 units/ml), sodium selenite (2.6 ng/ml) and apotransferrin (Sigma, 7.2 mg/ml) (S1 medium 50 ). NMuMG cells were grown on Geltrex-coated plastics and coverslips and were not found to form hollow acini when cultured in DMEM/(fetal bovine serum) FBS. HGF (hepatocyte growth factor) responsive MDCK cells 51 were kindly provided by Alan Prescott (University of Dundee) and grown in DMEM with 5% FBS. Breast cancer cell lines were cultured in the following media. MDA-MB-468 cells were grown in DMEM, 10% FBS. MCF-7 cells were grown in DMEM, 10% FBS, 2 mM glutamine. T-47D and MDA-MB 453 cells were grown in RPMI 1640, 10% FBS. MDA-MB 231 cells were grown in DMEM (low glucose þ pyruvate) and 10% FBS. BT-20 cells were grown in MEM and 10% FBS. All cells were grown at 37 1C, 5% CO 2 . HEK293T cells were cultured and lentiviral particles prepared as previously described. 37 NMuMG, MDCK and MDA-MB-468 cells were transduced with lentiviruses in media supplemented with 16 mg/ml of polybrene (hexadimethrine bromide, Sigma). The media was changed 24 h post transduction and cells were processed 4 days post transduction.
To establish matrigel suspension cultures, 4000 NMuMG or MDCK cells were seeded onto a gelled layer of matrigel (BD) on a 16 mm coverslip and after 1 h, excess media was aspirated. A second layer of Matrigel was added, and the cells were incubated in their respective media. Culture media were changed every 3 days. Typically NMuMG cells were left to form acini for 7-10 days before scoring. Cell colonies with one distinct central hollow lumen were scored blind using a phase contrast microscope to allow rapid focusing through each colony. Proliferation of matrigel cultures PI3K PTEN and epithelial architecture FM Berglund et al was performed using a Lactate Dehydrogenase (LDH) assay kit purchased from Roche (Welwyn Garden City, UK) as previously described. 37 Expression and RNA interference constructs and E545K were kindly provided by Jon Backer and have been described previously. 52 A cDNA encoding human HER2 was obtained from IMAGE/ Source Biosciences and through the insertion of a linker, cloned into the lentiviral vector pHR-SIN-IRES-puro using MluI-XbaI/SpeI restriction endonuclease digestion. A lentiviral vector based upon pHR-SIN and encoding human AKT1 was kindly provided by Dario Alessi and the introduction of the E17K mutation has been previously described along with the description of the lentiviral vectors encoding untagged human PTEN and its mutants. 39 Four silent mutations that render the PTEN cDNA resistant to the PTEN targeting shRNA (both sh2 and sh3) were introduced by site-directed mutatgenesis with the oligonucleotide 5 0 -GAAGACCATAAC CCACCACAGCTTGAGCTAATTAAACCCTTTTGTGAAGATC-3 0 and its reverse complement. The generation of the 399X and X404L PTEN mutants has been described elsewhere. 53 
Immunofluorescence and immunoblotting
NMuMG and MDCK cells grown in 3D matrigel were fixed in 2% paraformaldehyde for 30 min, permeablised in tris-buffered saline 0.1% Triton for 30 min and then blocked in tris-buffered saline-T 2% fish skin gelatin for 1-2 h. TRITC labelled phalloidin (1:1000 dilution, overnight incubation at 4 1C) (Sigma) was used to visualise F-actin. DNA was stained with DAPI (1:10 000). To visualise apoptotic cells, an antibody against cleaved caspase 3 (rabbit polyclonal, Cell Signalling Technology, Danvers, MA, USA, 1:100 dilution) was used, together with an anti-rabbit Alexa568 conjugated secondary antibody. Etopside treated (42.5 mM, 22 h) NMuMG cells in 3D matrigel was used as a positive control for caspase 3 staining. Matrigel suspension cultures were visualised using a 2 photon microscope (Biorad radiance, Hemel Hempstead, UK), and images were processed using Volocity. Antibodies raised against b-catenin, ZO-1 and occludin were from BD Transduction Laboratories (Oxford, UK).
For protein analysis of cell lysates, adherent cells were washed twice in ice-cold phosphate-buffered saline and lysed in ice-cold buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EGTA, 1mM EDTA, 5 mM sodium pyrophosphate, 10 mM b-glycerophosphate and 50 mM sodium fluoride) containing freshly added complete protease inhibitor cocktail (Roche, mini EDTA-free), 1 mM sodium orthovanadate and 0.1% 2-mercaptoethanol. Equal amounts of protein were separated by SDS-PAGE using pre-cast 4-12% gradient gels (Invitrogen) and blotted onto PVDF membranes (Polyscreen; NEN/PerkinElmer, Millipore, Watford, UK). Most reagents for electrophoresis and blotting were purchased from Invitrogen, and standard manufacturers' protocols were followed. Quantitation of blotting data was performed using AIDA densitometry software to analyse images obtained either directly from blots using a CDD camera or from processed film using a transmission scanner. Antibodies were from the following suppliers: PTEN, mouse monoclonal A2B1 (Santa Cruz, Heidelberg, Germany); GAPDH, mouse monoclonal, (Millipore, Heidelberg, Germany); P-AKT T308, rabbit polyclonal (Cell Signalling Technology); P-AKT S473, rabbit polyclonal (Cell Signalling Technology); total AKT, mouse monoclonal (Cell Signalling Technology), Cyclin D3 (BD Transduction Laboratories).
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